Participated · Series A · Jun 2023

RxLightning offers the industry’s first comprehensive platform for streamlining specialty medication access and affordability. Its MedAccess Ecosystem digitizes and automates the multi-step specialty medication onboarding process across providers, specialty pharmacies, patients, and drug manufacturers. The platform has digitized forms for over 1,200 specialty drugs with custom logic and smart-pick menus, automates FDA REMS requirements, confirms patient eligibility and coverage, and streamlines enrollment in financial assistance programs. RxLightning's workflow reduces administrative burden so onboarding can be completed in minutes or hours rather than days or weeks, and the service is available at no cost to healthcare providers. The company plans to use the new capital to scale medication access capabilities, expand infrastructure and personnel, and continue growing its partner base. Financially, the company closed a $17.5M Series A and has raised $20.5M in total capital since inception. RxLightning digitizes, automates and streamlines the manual specialty medication enrollment process through a single, user-friendly platform. The company’s solution enables providers to complete enrollment for every specialty medication across therapeutic areas, reducing paperwork and accelerating therapy initiation for patients. RxLightning says its digital approach is gaining rapid market interest and adoption. The announcement notes specialty medications are expected to account for 70% of new medication launches through 2023, underscoring market opportunity. RxLightning was founded in New Albany, Indiana in 2020 and offers its platform to healthcare providers. The company recently closed a financing round and added new board members following the raise.